ArticleBreast cancer research : BCR2025

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.

Gilda Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.